Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab with Chemoradiotherapy for Elderly Locally Advanced Esophageal Squamous Cell Carcinoma
NCT06354218Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Jiangsu Provincial People's Hospital. Started Dec 2023; status: recruiting.
02
Drugs
serplulimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06354218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06354218.